Predictive Role of MRI and ¹⁸F FDG PET Response to Concurrent Chemoradiation in T2b Cervical Cancer on Clinical Outcome: A Retrospective Single Center Study

• Main Authors: Anna Myriam Perrone, Giulia Dondi, Manuela Coe, Martina Ferioli, Silvi Telo, Andrea Galuppi, Eugenia De Crescenzo, Marco Tesei, Paolo Castellucci, Cristina Nanni, Stefano Fanti, Alessio G. Morganti, Pierandrea De Iaco
• Format: Article
• Language: English
• Published: MDPI AG 2020-03-01
• Series: Cancers
• Subjects: locally advanced cervical cancer; pet/ct; mri; concurrent chemoradiotherapy; treatment response; follow up
• Online Access: https://www.mdpi.com/2072-6694/12/3/659

Tumor response in locally advanced cervical cancer (LACC) is generally evaluated with MRI and PET, but this strategy is not supported by the literature. Therefore, we compared the diagnostic performance of these two techniques in the response evaluation to concurrent chemoradiotherapy (CCRT) in LACC. Patients with cervical cancer (CC) stage T2b treated with CCRT and submitted to MRI and PET/CT before and after treatment were enrolled in the study. All clinical, pathological, therapeutic, radiologic and follow-up data were collected and examined. The radiological response was analyzed and compared to the follow-up data. Data of 40 patients with LACC were analyzed. Agreement between MRI and PET/CT in the evaluation response to therapy was observed in 31/40 (77.5%) of cases. The agreement between MRI, PET/CT and follow-up data showed a Cohen kappa coefficient of 0.59 (95% CI = 0.267−0.913) and of 0.84 (95% CI = 0.636−1.00), respectively. Considering the evaluation of primary tumor response, PET/CT was correct in 97.5% of cases, and MRI in 92.5% of cases; no false negative cases were observed. These results suggest the use of PET/CT as a unique diagnostic imaging tool after CCRT, to correctly assess residual and progression disease.